| Dr Mohammad H Arbabi, MD | |
|
6500 France Ave S, Edina, MN 55435-1700 | |
| (952) 924-8117 | |
| (844) 422-7933 |
| Full Name | Dr Mohammad H Arbabi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 6500 France Ave S, Edina, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003809898 | NPI | - | NPPES |
| 948292 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 34304 (Arizona) | Primary |
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
Women experience chronic pain longer, more intensely and more often than men, according to a psychologist who works with both men and women dealing with diseases and conditions that leave them suffering.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
For a number of innovative and life-saving medical treatments, from organ replacements and skin grafts to cancer therapy and surgery, success often depends on slipping past or fending off the body's immune system.
The discovery of a gene, called PRDM1, as a tumor suppressor sheds new light on the cause - and possible treatment - of diffuse large B-cell lymphomas (DLBCLs), a cancer of the blood's B-lymphocytes. DLBCLs comprise about 30 percent of non-Hodgkin's lymphomas.
› Verified 2 days ago
| Entity Name | Fairview Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346432218 PECOS PAC ID: 7113830142 Enrollment ID: O20031106000516 |
News Archive
Women experience chronic pain longer, more intensely and more often than men, according to a psychologist who works with both men and women dealing with diseases and conditions that leave them suffering.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
For a number of innovative and life-saving medical treatments, from organ replacements and skin grafts to cancer therapy and surgery, success often depends on slipping past or fending off the body's immune system.
The discovery of a gene, called PRDM1, as a tumor suppressor sheds new light on the cause - and possible treatment - of diffuse large B-cell lymphomas (DLBCLs), a cancer of the blood's B-lymphocytes. DLBCLs comprise about 30 percent of non-Hodgkin's lymphomas.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mohammad H Arbabi, MD 3400 W 66th St Ste 290, Edina, MN 55435-2133 Ph: (952) 914-1720 | Dr Mohammad H Arbabi, MD 6500 France Ave S, Edina, MN 55435-1700 Ph: (952) 924-8117 |
News Archive
Women experience chronic pain longer, more intensely and more often than men, according to a psychologist who works with both men and women dealing with diseases and conditions that leave them suffering.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
For a number of innovative and life-saving medical treatments, from organ replacements and skin grafts to cancer therapy and surgery, success often depends on slipping past or fending off the body's immune system.
The discovery of a gene, called PRDM1, as a tumor suppressor sheds new light on the cause - and possible treatment - of diffuse large B-cell lymphomas (DLBCLs), a cancer of the blood's B-lymphocytes. DLBCLs comprise about 30 percent of non-Hodgkin's lymphomas.
› Verified 2 days ago
Jonathan Avery Reynolds, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6401 France Ave S, Edina, MN 55435 Phone: 952-924-5000 | |
Christopher Stefonowicz, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7450 France Ave S Ste 100, Edina, MN 55435 Phone: 952-832-8100 | |
Anne Marie Rosenberg, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7500 France Ave S, Edina, MN 55435 Phone: 952-835-1311 | |
David Lewis Bowlin, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6363 France Ave S, Suite 400, Edina, MN 55435 Phone: 952-920-2070 Fax: 952-920-7444 | |
Jody Kay Hargrove, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7600 France Ave S Ste 5100, Edina, MN 55435 Phone: 952-893-1959 Fax: 952-893-1954 | |
Jeffrey Lee Wilson, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7600 France Ave S Ste 5100, Edina, MN 55435 Phone: 952-893-1959 Fax: 952-893-1954 |